Target Therapeutics
This article was originally published in The Gray Sheet
Executive Summary
Adopts stockholders rights plan in response to "increased levels of acquisition activity in the healthcare industry." The company says it is not aware of any proposed acquisition of the firm. The rights, which are exercisable 10 days after the acquisition of or tender offer for 15% or more of Target's common stock, entitle shareholders (other than the potential acquiring entity) to purchase stock, and in some cases cash or property, with a market value of twice the exercise price. The rights also allow shareholders to purchase one one-thousandth of a share of the company's Series A participating preferred stock for $135
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.